Tuesday 26 June 2018
A letter has been submitted to the Australian Commission on Safety and Quality in Health Care by each state’s Pelvic Mesh Support Groups and the Health Consumer organisations in each State and Territory across Australia, asking the Commission to comprehensively address the recommendations tabled in the Senate Report. You can download a copy of the letter below.
The Australian Commission on Safety and Quality in Health Care have released two consumer resources to assist and support to women who are considering treatment options in regard to Pelvic Organ Prolapse and Stress Urinary Incontinence. The resources were developed in consultation with many women across the country, who shared their lived experience at various meetings around the country. You can view both of the resources below.
The Australian Government is making changes to Medicare-funded urogynaecological services relating to pelvic organ prolapse repair, based on advice from the Medicare Benefits Schedule (MBS) Review Taskforce. You can view the factsheet below.
The Royal Australian College of General Practitioners (RACGP) has released a statement for General Practitioners outlining the impact of the senate enquiry on future treatment options. It outlines recommendations on how to treat women who have had mesh inserted and are exhibiting adverse symptoms, and information about treatment of women who experience pelvic organ prolapse and stress urinary incontinence. You can read the article here.
The Senate Report on The number of women in Australia who have had transvaginal mesh implants and related matters was released on 28 March 2018, and can be found here.
Australia’s state and territory based health consumer organisations have welcomed the recognition of the extent and impact of harm to women, and the recommendations contained in the Senate report. But they say they hoped the report had gone further. You can view their press release below.
A joint media release by Pelvic Mesh Support Groups across Australia is also available below.
Consumers Health Forum of Australia has also issued the media release below, in response to the Senate Report.
HCA is working with consumers, specialists and SA Health to develop a model of care for South Australian women, to support women who have been injured through the use of vaginal mesh.
You can find further information on the Australian Commission for Safety and Quality in Health Care website here.
On 28 November 2017, the Therapeutic Goods Administration (TGA) advised of the decision to remove transvaginal mesh products which have the sole use as the treatment of pelvic organ prolapse (POP) via transvaginal implantation from the Australian Register of Therapeutic Goods (ARTG).
The TGA website provides detail of this decision here.